Novartis AG (NVSEF) Capital expenditures 2016–2025
Novartis AG (NVSEF) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$1.5BFY2025 · since FY2016: $1.9B → $1.5B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $1.5B | +13.3% |
| FY2024 | $1.4B | +28.9% |
| FY2023 | $1.1B | +15.7% |
| FY2022 | $916.0M | -14.1% |
| FY2021 | $1.1B | -16.4% |
| FY2020 | $1.3B | -7.5% |
| FY2019 | $1.4B | +10.0% |
| FY2018 | $1.3B | -5.4% |
| FY2017 | $1.3B | -28.8% |
| FY2016 | $1.9B | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice
More NVSEF financial trends
NVSEF RevenueNVSEF Net incomeNVSEF Net marginNVSEF Gross profitNVSEF Gross marginNVSEF Operating incomeNVSEF Operating marginNVSEF Operating cash flowNVSEF Free cash flowNVSEF Return on equityNVSEF Stock buybacksNVSEF Dividends paidNVSEF Total assetsNVSEF Total liabilitiesNVSEF Shareholders’ equityNVSEF overview →